移植后高脂血症
Post-transplant hyperlipidaemia.
作者信息
Jindal R M
机构信息
Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA.
出版信息
Postgrad Med J. 1997 Dec;73(866):785-93. doi: 10.1136/pgmj.73.866.785.
Abstract
The correction of post-transplant hyperlipidaemia warrants the judicious and timely use of pharmacological agents with dietary modification and exercise. Reduction in hyperlipidaemia may have some role in decreasing the incidence of chronic rejection of allografts. The awareness that the morbidity and mortality of atherosclerotic disease may be lowered by active intervention will result in a better quality of life for transplant recipients.
摘要
移植后高脂血症的纠正需要合理且及时地使用药物，并配合饮食调整和运动。降低高脂血症可能在降低同种异体移植物慢性排斥反应的发生率方面发挥一定作用。认识到通过积极干预可以降低动脉粥样硬化疾病的发病率和死亡率，将有助于提高移植受者的生活质量。
相似文献
1
Post-transplant hyperlipidaemia.
Postgrad Med J. 1997 Dec;73(866):785-93. doi: 10.1136/pgmj.73.866.785.
2
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Clin Transplant. 1997 Aug;11(4):299-312.
3
Tacrolimus in transplant rejection.
Expert Opin Pharmacother. 2013 Jan;14(1):115-22. doi: 10.1517/14656566.2013.751374. Epub 2012 Dec 10.
4
Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Pediatr Transplant. 2006 Sep;10(6):721-9. doi: 10.1111/j.1399-3046.2006.00577.x.
5
Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Cochrane Database Syst Rev. 2013 May 31(5):CD008817. doi: 10.1002/14651858.CD008817.pub2.
6
Hyperlipidaemia in immunosuppression.
Curr Opin Lipidol. 2016 Dec;27(6):631-632. doi: 10.1097/MOL.0000000000000363.
7
Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both?
Transplantation. 2003 Jul 27;76(2):446-7; author reply 447-8. doi: 10.1097/01.TP.0000077419.91788.30.
8
The metabolic effects of cyclosporin and tacrolimus.
J Endocrinol Invest. 2000 Jul-Aug;23(7):482-90. doi: 10.1007/BF03343761.
9
Calcineurin inhibitors in renal transplantation: what is the best option?
Drugs. 2003;63(15):1535-48. doi: 10.2165/00003495-200363150-00002.
10
Refractory Dyslipidemia After Liver Transplant: Case Study With Successive Histologic Investigations.
Exp Clin Transplant. 2015 Aug;13(4):371-5. doi: 10.6002/ect.2014.0051. Epub 2015 Apr 28.
引用本文的文献
1
Transplant endocrinology.
Med J Armed Forces India. 2023 Nov-Dec;79(6):651-656. doi: 10.1016/j.mjafi.2023.08.017. Epub 2023 Sep 12.
2
Calcineurin inhibitors and post-transplant hyperlipidaemias.
Drug Saf. 2001;24(10):755-66. doi: 10.2165/00002018-200124100-00004.
本文引用的文献
1
Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management.
Liver Transpl Surg. 1995 Sep;1(5 Suppl 1):29-38.
2
Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management.
Arch Intern Med. 1997 Feb 10;157(3):273-80.
3
Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
Transplantation. 1997 Jan 15;63(1):39-47. doi: 10.1097/00007890-199701150-00008.
4
Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
Transplantation. 1996 Oct 15;62(7):934-42. doi: 10.1097/00007890-199610150-00011.
5
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
6
The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.
Kidney Int. 1996 Jan;49(1):209-16. doi: 10.1038/ki.1996.28.
7
Metabolic problems in recipients of liver transplants.
Clin Transplant. 1996 Apr;10(2):213-7.
8
Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention.
Ann Intern Med. 1996 Jan 1;124(1 Pt 2):123-6. doi: 10.7326/0003-4819-124-1_part_2-199601011-00008.
9
Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?
Ann Intern Med. 1996 Jan 1;124(1 Pt 2):110-6. doi: 10.7326/0003-4819-124-1_part_2-199601011-00006.
10
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Ann Pharmacother. 1995 Sep;29(9):879-91. doi: 10.1177/106002809502900911.
Zotero 插件